Palanosetron 0.25

Palonosetron 0.25 mg Injection
Palonosetron 0.25 mg Injection is a long-acting selective 5-HT3 receptor antagonist used for the prevention of nausea and vomiting associated with chemotherapy. It is especially effective in preventing both acute and delayed chemotherapy-induced nausea and vomiting (CINV) and is widely used in modern oncology supportive care protocols.
Product Details
Generic Name: Palonosetron (as Palonosetron Hydrochloride)
Strength: 0.25 mg
Dosage Form: Injection (Sterile solution)
Route of Administration: Intravenous (IV)
Therapeutic Class: Antiemetic (5-HT3 Receptor Antagonist)
Indications
Palonosetron 0.25 mg Injection is indicated for:
Prevention of acute chemotherapy-induced nausea and vomiting (CINV)
Prevention of delayed chemotherapy-induced nausea and vomiting
Use in moderately and highly emetogenic chemotherapy regimens
Mechanism of Action
Palonosetron works by selectively blocking serotonin (5-HT3) receptors in the central nervous system and gastrointestinal tract, preventing the vomiting reflex triggered by chemotherapy.
Key Benefits
Long-acting antiemetic with extended half-life
Effective against both acute and delayed CINV
Requires single-dose administration per chemotherapy cycle
Well-tolerated with minimal side effects
Widely accepted in global oncology guidelines
Dosage & Administration
Palonosetron 0.25 mg is usually administered as a single IV dose prior to the start of chemotherapy. Dosage and timing should be as directed by the treating physician.
Storage Conditions
Store below 25°C
Protect from light
Do not freeze
Precautions
For hospital and clinical use only
Use under medical supervision
Use with caution in patients with known hypersensitivity